DSIP + Selank

Where the name "DSIP + Selank" comes from

"DSIP + Selank" is market and community usage. Peptide Health Lab neither coined it nor endorses it, and this page exists because the two names are sold and searched next to each other, not because a literature exists behind the pairing.

Where that pairing came from is not documented in the indexed literature. A PubMed search for DSIP AND Selank on 1 September 2026 returned 1 record: a 2026 narrative review of therapeutic peptides in orthopaedics, which places delta sleep-inducing peptide among "recovery-enhancing agents" in one clause of one sentence and Selank among "neuroactive peptides" in the next, proposes no pairing, and administers nothing. The same review states plainly that although the preclinical work is promising, clinical trials are currently lacking.^[1] Nothing found on that date proposes the combination, defines its composition, or names a clinic or a paper that introduced it.

What's in it and why people combine them

DSIP is a peptide whose identity was never resolved. It was isolated from rabbit cerebral venous blood in 1977 and treated as a candidate sleep-promoting factor, and a 2006 review by researchers who had worked on it describes the state of that hypothesis without softening: the DSIP gene, protein and any related receptor have never been isolated, the link to sleep was never further characterized, and the sleep-factor hypothesis is extremely poorly documented and weak. The same review notes that certain artificial structural analogues of DSIP promoted slow-wave sleep in rabbits and rats where DSIP itself did not.^[6] The human work is small and old. Sixteen chronic insomniacs, double-blind, intravenous: sleep efficiency and sleep latency separated from placebo, and the authors' own conclusion was that the significant effects were weak, possibly attributable to a change in the placebo group, and unlikely to be of major therapeutic benefit.^[5]

Selank is a synthetic analogue of tuftsin developed in Moscow and studied almost entirely as an anxiolytic. Its human record includes an unblinded comparison against a benzodiazepine in which it was given as an add-on rather than instead of one.^[4]

The rationale offered for putting them together is that one is described as acting on sleep and the other on anxiety. That is an argument about two mechanisms sitting next to each other. It is not a result, and no measurement anywhere in the indexed record was taken with both peptides present.

What the evidence says about the combination

No published study has administered DSIP and Selank together. On 1 September 2026, PubMed returned 1 record for DSIP AND Selank, 1 record for "delta sleep-inducing peptide" AND Selank, and 0 records for Selank AND DSIP AND (combination OR combined OR co-administration OR coadministration); the single record in the first two searches is the same narrative review, which administers nothing.^[1] Because a keyword search can miss a paper that spells a compound differently, the same searches were run against PubMed's controlled vocabulary on the same date: selank[nm] AND "Delta Sleep-Inducing Peptide"[Mesh] returned 0 records, and "TP 7"[nm] AND "Delta Sleep-Inducing Peptide"[Mesh], using Selank's other indexed substance name, also returned 0.

What makes that absence worth stating is that it is specific rather than general. Both of these peptides have been given alongside a second agent in published, indexed experiments; the database can find those studies. A PubMed search on 1 September 2026 for "Delta Sleep-Inducing Peptide"[Mesh] AND "Drug Therapy, Combination"[Mesh] returned 4 records. In one, rats with fully developed metaphit-induced audiogenic seizures received intraperitoneal valproate and DSIP alone or in combination; combined treatment was more effective than the drugs alone, especially in the four hours after administration, and none of the dose combinations tested eliminated the EEG signs of epileptiform activity.^[2] In another, rats resuscitated after twelve minutes of clinical death received mexidol, DSIP and oxytocin individually and in combination; recovery improved under both individual and combination treatment, and the authors single out mexidol with oxytocin — the pairing without DSIP in it — as the one that most significantly promoted recovery of central nervous system function.^[3] On Selank's side, a PubMed search for selank[nm] AND "Drug Therapy, Combination"[Mesh] on the same date returned 1 record, the phenazepam add-on study.^[4]

So the field is capable of running a combination experiment on either of these molecules, has done so, and has published the results. It has never run one on this pair. That is why the combination claim on this page is graded anecdotal: not because the question is hard to search, but because the searches that would find an answer return nothing.

Where the evidence is weak

The two components do not share an endpoint. DSIP's human literature measures sleep, and the review that surveys the peptide reports DSIP-like immunoreactivity distributed in neurosecretory hypothalamic nuclei that are not particularly relevant for sleep regulation.^[6] Selank's literature measures anxiety. No study in either literature measures the other's outcome, so there is no published result the two could be said to converge on, and nothing to compare a combined effect against even if someone ran one.

The one human combination trial involving either component points the other way. Among the benzodiazepine effects the Selank add-on regimen was reported to reduce were sedation and increased sleep duration — an effect on sleep in the opposite direction from the one DSIP is named for. Nothing in the published record addresses what a peptide described as sleep-promoting and a peptide reported to blunt sedation do in each other's presence, in a person or an animal.^[4]

DSIP's strongest human result is also its weakest. Its authors reported statistically significant improvements and then, in the same abstract, called those effects weak, attributed part of them to an incidental change in the placebo group, and concluded against major therapeutic benefit.^[5] A page that reported only the first half of that sentence would be quoting a positive trial that its own authors did not think was one.

Dosing and protocol ranges are not on this page. They live on the individual compound pages, where each figure sits next to the population, route and study that produced it. There is no combined figure to carry here, because there is no combined study.

Questions to bring to a provider

The useful conversation is not whether this pairing is better than either component. It is what the symptom actually is and what has been shown to change it.

• If the target is sleep, what is the working diagnosis — sleep-onset insomnia, maintenance insomnia, a circadian problem, an untreated breathing disorder — and what does the evaluated standard of care offer for that specific one?
• Given that the DSIP sleep hypothesis rests on a peptide whose gene, protein and receptor have never been isolated, what would have to be true for it to be worth considering ahead of an evaluated option?^[6]
• Selank's human evidence involving a second agent is an add-on to a prescribed benzodiazepine. What does that imply for anyone already taking a sedative, an anxiolytic or a sleep medication?^[4]
• What objective measure would show whether anything changed — a validated sleep diary, actigraphy, a standardized anxiety scale at a fixed interval — and what result would end the experiment?

Anti-doping status

Neither DSIP nor Selank is named anywhere on the 2026 World Anti-Doping Agency Prohibited List, its Monitoring Program, or its Explanatory Note. All three documents were retrieved as published PDFs on 1 September 2026 by way of the United States Anti-Doping Agency's prohibited-list page, and searching the extracted text of all three for selank, delta sleep, DSIP and tuftsin returned zero occurrences.

The control that shows the search works covers one of those three documents, and is reported here as covering one. In the Prohibited List, control searches of the same extracted text for BPC-157, tesamorelin and MOTS-c each returned two occurrences, so a zero in that document describes the document rather than a broken search. The identical control terms return zero in the Monitoring Program and zero in the Explanatory Note, which establishes nothing about either — so neither of those two negatives rests on a text search. Both are short enumerated documents and both were read in full on the same date: the 2026 Monitoring Program is a single page listing six numbered categories, and the 2026 Explanatory Note is four pages of numbered modifications to named sections. Neither names either of these peptides. All of this was read from the documents themselves, not from any research paper.

An unlisted substance is not a permitted one. Section S0 reaches any pharmacological substance not addressed by another section of the List and with no current approval by any governmental regulatory health authority for human therapeutic use; all substances in that class are Specified Substances.

That criterion resolves for one component of this pairing and not for the other. No registration of DSIP by any national medicines regulator was found, so the conventional reading of S0 stands for it. Selank is the unresolved one: Russian pharmaceutical trade press, reporting on decisions the Russian Ministry of Health published on 20 January 2026, states that state registration of seventy-one medicines was cancelled at the registration holders' own request and names Selank among them — which describes a registration that existed until then. The Russian State Register of Medicines could not be queried to check either the registration or its cancellation: on 1 September 2026 its search endpoint returned HTTP 200 with no result rows, and a control query for a medicine certain to be registered returned the same, so the empty result is a failure of the query rather than a finding. This page therefore states no S0 conclusion for Selank, because the fact S0 turns on is the one it could not verify.

Nothing here is clearance; List standing and clinical standing are separate questions, and the 2026 orthopaedic review cited above describes the field it surveys as one where clinical trials are currently lacking.^[1] The List is reissued annually and sections renumber, so a competing athlete should confirm the current year's list with their national anti-doping organization rather than relying on this page.